Background Well tolerated antivirals administered early in the course of COVID-19 infection
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …

The novel coronavirus outbreak began in late December 2019 and rapidly spread
worldwide, critically impacting public health systems. A number of already approved and …

Introduction An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
was reported in Wuhan, China, in mid-December 2019, and declared a pandemic by the …

Background Despite vaccination, many remain vulnerable to coronavirus disease 2019
(COVID-19) and its complications. Oral antivirals to prevent COVID-19 progression are vital …

We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia
and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia …

Background Favipiravir is used to treat influenza, and studies demonstrate that it has
antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Objective To evaluate whether favipiravir reduces the time to viral clearance as documented
by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild …

Background COVID-19 has overwhelmed health services globally. Oral antiviral therapies
are licensed worldwide, but indications and efficacy rates vary. We aimed to evaluate the …

Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite …